NASDAQ · Biotechnology

GeoVax Labs, Inc. (GOVX) Stock

$0.28 -1.95% NASDAQ: GOVX Healthcare

Valuation

MetricValue
Price$0.28
Market Cap$2.07M
P/E Ratio-0.02
P/B Ratio0.83
P/S Ratio1.18
EPS (TTM)$-22.40
52-Week High$15.75
52-Week Low$0.28
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-743.66%
ROA-439.95%
ROCE-550.00%
Gross Margin-1100.00%
Operating Margin-1100.00%
Net Margin-1050.00%
Debt/Equity0.18
Current Ratio2.74

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$4.0M$2.0M
Operating Profit$-19.0M$-14.0M$-27.0M$-25.0M$-22.0M
Net Profit$-19.0M$-14.0M$-26.0M$-25.0M$-21.0M
EPS$-182.50$-138.00$-255.50$-120.50$-22.40
Op Margin-4862.7%-17207.5%—-635.8%-869.3%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$12.0M$31.0M$9.0M$8.0M$6.0M
Total Liabilities$7.0M$5.0M$4.0M$3.0M$3.0M
Cash$11.0M$28.0M$6.0M$6.0M$3.0M
Borrowings$0$0$0$0$1.0M

Latest News

GeoVax Highlights Strategic Alignment of GEO-MVA With HHS/ASPR's Five-Year Medical Countermeasure Preparedness Strategy NewMediaWire · Jul 21, 2026 GeoVax Highlights Continued U.S. Government Investment in Orthopox Preparedness as Strategic Validation of Long-Term Vaccine Readiness NewMediaWire · Jul 1, 2026 GeoVax Labs (GOVX) Stock Fair Value Moves Lower After Pipeline Shift Simply Wall St. · Jun 27, 2026 GeoVax Highlights Strategic Implications of Recent Gedeptin(R) Findings for Checkpoint-Resistant Cancers NewMediaWire · Jun 17, 2026 GeoVax Labs (GOVX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now Zacks · Jun 12, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-11.0M$-19.0M$-25.0M$-25.0M$-21.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$3.0M$8.0M$0$2.0M$0
Net Cash Flow$2.0M$16.0M$-21.0M$-1.0M$-2.0M
Free Cash Flow$-11.0M$-19.0M$-25.0M$-25.0M$-22.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA0.02
FCF Yield-779.23%
Quick Ratio1.54
Interest Coverage0.00
Return 1Y-94.14%
Return 3Y-99.54%
Return 5Y-99.94%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $336.64 -1.11% 38.93 $4.94T 0.32%
MSFTMicrosoft Corporation $535.07 +2.38% 28.68 $3.97T 0.76%
GOOGLAlphabet Inc. $351.66 +0.97% 16.94 $4.26T 0.26%
AMZNAmazon.com, Inc. $262.43 +3.29% 19.82 $2.82T 0.00%
METAMeta Platforms, Inc. $718.67 -0.31% 27.93 $1.83T 0.28%

About GeoVax Labs, Inc.

GeoVax Labs, Inc. is led by CEO David Alan Dodd, employs 17 people, headquartered in US, publicly traded since 2020.

GeoVax Labs, Inc. (GOVX) stock trades at $0.28 with a market capitalization of $2.07M. The stock is valued at a price-to-earnings (P/E) ratio of -0.02, price-to-book of 0.83, price-to-sales of 1.18. Over the past 52 weeks the stock has ranged between $0.28 and $15.75, and currently trades 98.2% below its 52-week high.

On profitability, GeoVax Labs, Inc. generates a return on equity (ROE) of -743.66%, return on capital employed of -550.00%, an operating margin of -1100.00%, a net profit margin of -1050.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides